Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 83.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,311 shares of the company’s stock after selling 133,009 shares during the period. American Century Companies Inc.’s holdings in Protagonist Therapeutics were worth $946,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. GSA Capital Partners LLP increased its stake in Protagonist Therapeutics by 179.8% during the first quarter. GSA Capital Partners LLP now owns 55,359 shares of the company’s stock worth $1,602,000 after acquiring an additional 35,571 shares during the last quarter. Vanguard Group Inc. grew its stake in Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the period. Kynam Capital Management LP increased its position in shares of Protagonist Therapeutics by 10.2% in the fourth quarter. Kynam Capital Management LP now owns 2,004,875 shares of the company’s stock worth $45,972,000 after acquiring an additional 186,218 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Protagonist Therapeutics in the 4th quarter valued at $4,606,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Protagonist Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock valued at $7,079,000 after acquiring an additional 17,065 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on PTGX. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. HC Wainwright boosted their price target on Protagonist Therapeutics from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, July 25th. BTIG Research boosted their target price on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, JMP Securities lowered their price target on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $49.86.

Insider Transactions at Protagonist Therapeutics

In related news, Director William D. Waddill sold 8,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $40.00, for a total value of $320,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at $480,000. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the sale, the chief financial officer now directly owns 34,960 shares of the company’s stock, valued at $1,555,370.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $40.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director now owns 12,000 shares in the company, valued at $480,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,203 shares of company stock valued at $1,311,891. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Trading Down 1.4 %

Protagonist Therapeutics stock opened at $44.37 on Wednesday. Protagonist Therapeutics, Inc. has a 52 week low of $13.72 and a 52 week high of $48.00. The stock has a market cap of $2.60 billion, a P/E ratio of 18.18 and a beta of 2.17. The stock has a 50 day moving average of $41.94 and a 200-day moving average of $34.40.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). The company had revenue of $4.17 million for the quarter, compared to the consensus estimate of $40.00 million. As a group, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.31 earnings per share for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.